Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs.
A new sustained release dosage form of valproic acid (VPA) was developed. The new sustained release dosage form was administered (twice, with and without food) to five dogs in comparison to a standard tablet (Depakine, Labaz) and an i.v. preparation of the drug. Drug level monitoring in the plasma was performed by a GLC assay. Results indicate that the sustained release formulation exhibited a more prolonged and uniform absorption rate, yielded more sustained plasma levels after ingestion, and showed an overall bioavailability of 0.84 (95 per cent C.I. = 0.72, 0.96) relative to an equivalent dose of a conventional tablet.
D000818:Animals; D003692:Delayed-Action Preparations; D004285:Dogs; D005260:Female; D007700:Kinetics; D008297:Male; D014635:Valproic Acid / Q000008:administration & dosage / Q000378:metabolism*
D003692:Delayed-Action Preparations; D014635:Valproic Acid